---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174954"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:06:57.161819+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks

## Summary
- FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.
- Cash, equivalents and marketable securities $607.7M; received $200M non-dilutive financing from Sagard.
- Product revenue net $1.2M from IBTROZI for 13 days of sales; collaboration revenue $3.6M (up from $1.4M).
- Net loss $59M ($0.17/sh) vs $462.5M ($1.89) in prior year which included AnHeart acquisition cost.
- NCCN guidelines added taletrectinib as preferred agent across lines of therapy for ROS1+ NSCLC.

## SEC filing metadata
- accession: 0001193125-25-174954
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/0001193125-25-174954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174954
- JSON: https://secwatch.observer/filing/0001193125-25-174954.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.